---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000046"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:12:38.341277+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M

## Summary
- Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.
- Q1 net revenue $9.1M (+5% ex-$3M prior-year milestone); net loss $3.3M; adjusted loss $0.13/share.
- FDA granted Fast Track Designation for ifetroban in Duchenne Muscular Dystrophy; Phase II study showed breakthrough results.
- Ended quarter with $11M cash, $5.2M drawn on credit facility, total assets $71M, equity $21.6M.

## SEC filing metadata
- accession: 0001087294-26-000046
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/0001087294-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/cpix-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000046
- JSON: https://secwatch.observer/filing/0001087294-26-000046.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000046.txt

## Source-grounded claims
- claim_id: 2923a815c5d9df7160069f91e9201e7278ecf2df
  claim: CUMBERLAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $9.1 million, net income net loss for the first quarter of 2026 was approximately $3.3 million, EPS $0.13 per share.
  evidence_excerpt: Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/0001087294-26-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.